Design, Synthesis, and Neuroprotective Activity of Phenoxyindole Derivatives on Antiamyloid Beta (Aβ) Aggregation, Antiacetylcholinesterase, and Antioxidant Activities

In this investigation, a number of phenoxyindole derivatives were designed, synthesized, and tested for their neuroprotective ability on SK-N-SH cells against Aβ42-induced cell death and biologically specific activities involved in anti-Aβ aggregation, anti-AChE, and antioxidant effects. The proposed compounds, except compounds 9 and 10, could protect SK-N-SH cells at the IC50 of anti-Aβ aggregation with cell viability values ranging from 63.05% ± 2.70% to 87.90% ± 3.26%. Compounds 3, 5, and 8 demonstrated striking relationships between the %viability of SK-N-SH cells and IC50 values of anti-Aβ aggregation and antioxidants. No significant potency of all synthesized compounds against AChE was found. Among them, compound 5 showed the strongest anti-Aβ and antioxidant properties with IC50 values of 3.18 ± 0.87 and 28.18 ± 1.40 μM, respectively. The docking data on the monomeric Aβ peptide of compound 5 demonstrated good binding at regions involved in the aggregation process, and the structural feature made it possible to be a superior radical scavenger. The most effective neuroprotectant belonged to compound 8, with a cell viability value of 87.90% ± 3.26%. Its unique mechanisms for enhancing the protective impact may serve additional purposes since it demonstrated mild biological-specific effects. In silico prediction of CNS penetration shows strong passive penetration ability across the blood–brain barrier from blood vessels to the CNS for compound 8. In light of our findings, compounds 5 and 8 appeared as potentially intriguing lead compounds for new therapeutic approaches to Alzheimer’s disease. More in vivo testing will be revealed in due course.

[1]  Yue-Ming Li,et al.  Recent developments of small molecule γ-secretase modulators for Alzheimer's disease. , 2020, RSC medicinal chemistry.

[2]  M. Narayan,et al.  The Potential Role of Natural Polyphenols Against Protein Aggregation Toxicity: In Vitro, In Vivo, and Clinical studies. , 2020, ACS chemical neuroscience.

[3]  B. de Strooper,et al.  The β-Secretase BACE1 in Alzheimer’s Disease , 2020, Biological Psychiatry.

[4]  T. Amelsvoort,et al.  The effect of curcumin on cognition in Alzheimer’s disease and healthy aging: A systematic review of pre-clinical and clinical studies , 2019, Brain Research.

[5]  M. Valko,et al.  Management of oxidative stress and other pathologies in Alzheimer’s disease , 2019, Archives of Toxicology.

[6]  P. Genevaux,et al.  (Bio)Chemical strategies to modulate amyloid-β self-assembly. , 2019, ACS chemical neuroscience.

[7]  K. Irie,et al.  Three Structural Features of Functional Food Components and Herbal Medicine with Amyloid β42 Anti-Aggregation Properties , 2019, Molecules.

[8]  C. Faustino,et al.  Therapeutic Strategies Targeting Amyloid-β in Alzheimer's Disease. , 2019, Current Alzheimer research.

[9]  O. Pansarasa,et al.  Curcumin and Novel Synthetic Analogs in Cell-Based Studies of Alzheimer’s Disease , 2018, Front. Pharmacol..

[10]  Deepti Goyal,et al.  Benzofuran and Indole: Promising Scaffolds for Drug Development in Alzheimer's Disease , 2018, ChemMedChem.

[11]  M. Abdollahi,et al.  Cinnamon, a promising prospect towards Alzheimer's disease , 2017, Pharmacological research.

[12]  M. Tomás,et al.  Oxidative stress and the amyloid beta peptide in Alzheimer’s disease , 2017, Redox biology.

[13]  R. Reiter,et al.  Mechanisms of Melatonin in Alleviating Alzheimer’s Disease , 2017, Current neuropharmacology.

[14]  C. Moussa Beta-secretase inhibitors in phase I and phase II clinical trials for Alzheimer’s disease , 2017, Expert opinion on investigational drugs.

[15]  T. Mohamed,et al.  Amyloid cascade in Alzheimer's disease: Recent advances in medicinal chemistry. , 2016, European journal of medicinal chemistry.

[16]  B. Reif,et al.  Sulindac Sulfide Induces the Formation of Large Oligomeric Aggregates of the Alzheimer's Disease Amyloid-β Peptide Which Exhibit Reduced Neurotoxicity. , 2016, Biochemistry.

[17]  T. Mohamed,et al.  Structure-Activity Relationship Studies of Isomeric 2,4-Diaminoquinazolines on β-Amyloid Aggregation Kinetics. , 2016, ACS medicinal chemistry letters.

[18]  S. N. Bukhari,et al.  Synthetic Curcumin Analogs as Inhibitors of β -Amyloid Peptide Aggregation: Potential Therapeutic and Diagnostic Agents for Alzheimer's Disease. , 2015, Mini reviews in medicinal chemistry.

[19]  Arun K. Ghosh,et al.  Prospects of β‐Secretase Inhibitors for the Treatment of Alzheimer’s Disease , 2015, ChemMedChem.

[20]  P. Mishra,et al.  Perspectives on Inhibiting β‐Amyloid Aggregation through Structure‐Based Drug Design , 2015, ChemMedChem.

[21]  T. Govindaraju,et al.  Function and toxicity of amyloid beta and recent therapeutic interventions targeting amyloid beta in Alzheimer's disease. , 2015, Chemical communications.

[22]  A. Doig,et al.  Inhibition of protein aggregation and amyloid formation by small molecules. , 2015, Current opinion in structural biology.

[23]  Jeffrey S Derrick,et al.  The ongoing search for small molecules to study metal-associated amyloid-β species in Alzheimer's disease. , 2014, Accounts of chemical research.

[24]  Xingshu Li,et al.  New multi-target-directed small molecules against Alzheimer's disease: a combination of resveratrol and clioquinol. , 2014, Organic & biomolecular chemistry.

[25]  G. Keserű,et al.  Structure-based β-secretase (BACE1) inhibitors. , 2014, Current pharmaceutical design.

[26]  S. Lichtenthaler Alpha-secretase cleavage of the amyloid precursor protein: proteolysis regulated by signaling pathways and protein trafficking. , 2012, Current Alzheimer research.

[27]  K. Kuča,et al.  Assessment of Acetylcholinesterase Activity Using Indoxylacetate and Comparison with the Standard Ellman’s Method , 2011, International journal of molecular sciences.

[28]  M. Geng,et al.  Small molecule inhibitors of amyloid β peptide aggregation as a potential therapeutic strategy for Alzheimer's disease , 2011, Acta Pharmacologica Sinica.

[29]  R. Wickner,et al.  Structural Insights into Functional and Pathological Amyloid* , 2011, The Journal of Biological Chemistry.

[30]  R. Singh,et al.  Genesis and development of DPPH method of antioxidant assay , 2011, Journal of food science and technology.

[31]  A. Miranker,et al.  Protein-induced photophysical changes to the amyloid indicator dye thioflavin T , 2010, Proceedings of the National Academy of Sciences.

[32]  B. Reif,et al.  Amyloid beta 42 peptide (Aβ42)-lowering compounds directly bind to Aβ and interfere with amyloid precursor protein (APP) transmembrane dimerization , 2010, Proceedings of the National Academy of Sciences.

[33]  N. Grigorieff,et al.  Comparison of Alzheimer Aβ(1–40) and Aβ(1–42) amyloid fibrils reveals similar protofilament structures , 2009, Proceedings of the National Academy of Sciences.

[34]  Tak W. Kee,et al.  The thioflavin T fluorescence assay for amyloid fibril detection can be biased by the presence of exogenous compounds , 2009, The FEBS journal.

[35]  J. Gestwicki,et al.  Structure–activity Relationships of Amyloid Beta‐aggregation Inhibitors Based on Curcumin: Influence of Linker Length and Flexibility , 2007, Chemical biology & drug design.

[36]  R. Riek,et al.  3D structure of Alzheimer's amyloid-β(1–42) fibrils , 2005 .

[37]  R. Tycko,et al.  Abeta40-Lactam(D23/K28) models a conformation highly favorable for nucleation of amyloid. , 2005, Biochemistry.

[38]  R. Bhat,et al.  Mechanisms of tauopathies , 2004 .

[39]  C. Haass Take five—BACE and the γ‐secretase quartet conduct Alzheimer's amyloid β‐peptide generation , 2004 .

[40]  Gerd Buntkowsky,et al.  Solid State NMR Reveals a pH-dependent Antiparallel β-Sheet Registry in Fibrils Formed by a β-Amyloid Peptide , 2004 .

[41]  V. Andrisano,et al.  beta-Amyloid aggregation induced by human acetylcholinesterase: inhibition studies. , 2003, Biochemical pharmacology.

[42]  B Testa,et al.  Predicting blood-brain barrier permeation from three-dimensional molecular structure. , 2000, Journal of medicinal chemistry.

[43]  T. Wisniewski,et al.  Biology of Aβ Amyloid in Alzheimer's Disease , 1997, Neurobiology of Disease.

[44]  R. Castellani,et al.  Molecular Pathology of Alzheimer's Disease , 2013 .

[45]  D. Scudiero,et al.  Tetrazolium-based assays for cellular viability: a critical examination of selected parameters affecting formazan production. , 1991, Cancer research.

[46]  I. I. Grandberg,et al.  New data on the mechanism of the Fischer indole synthesis (review) , 1988 .

[47]  G. S. Bajwa,et al.  Fischer indole synthesis. The reaction of N′-methyl-2,6-dimethylphenylhydrazine hydrochloride with 2-methylcyclohexanone and 2,6-dimethylcyclohexanone , 1970 .

[48]  G. Hughes,et al.  The Fischer Indole Synthesis , 1949, Nature.

[49]  Mengxi Tang,et al.  The Mechanisms of Action of Curcumin in Alzheimer's Disease. , 2017, Journal of Alzheimer's disease : JAD.

[50]  J. Hardy,et al.  The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .

[51]  J. D. Figueroa-Villar,et al.  Organophosphorus compounds as chemical warfare agents: a review , 2009 .

[52]  C. Haass,et al.  Alzheimer disease gamma-secretase: a complex story of GxGD-type presenilin proteases. , 2002, Trends in cell biology.